UK regulators have approved a drug treatment to tackle the new Omicron variant of Covid-19. The drug, known as Xevudy (sotrovimab, and made by pharmaceutical giant GlaxoSmithKline (GSK), has been found to cut hospital admission and death by 79 per cent for those at risk.
The medicines and Healthcare products Regulatory Agency has authorised the monoclonal antibody for people with mild to moderate Covid-19 who are at high risk of suffering from complications with the disease. Read more: It comes as GSK and Vir Biotechnology said preclinical data shows the drug “retains activity against key mutations of the new Omicron Sars-CoV-2 variant”.